title: Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine.
authors.affiliation: Department of Hematology-Oncology, National University Cancer Institute of Singapore, Singapore, Singapore.
authors.forename: Li-Mei
authors.initials: LM
authors.lastname: Poon
authors.affiliation: Department of Medicine, Queen Mary Hospital, Professorial Block, Pokfulam Road, Hong Kong, China. ylkwong@hkucc.hku.hk.
authors.forename: Yok-Lam
authors.initials: YL
authors.lastname: Kwong
mesh_terms: D000293:Adolescent; D064591:Allografts; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride / Q000008:administration & dosage; D000079963:Brentuximab Vedotin; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage; D016130:Immunophenotyping; D017730:Ki-1 Antigen / Q000032:analysis / Q000276:immunology; D054391:Lymphoma, Extranodal NK-T-Cell / Q000188:drug therapy* / Q000628:therapy / Q000821:virology; D054446:Lymphoma, Primary Cutaneous Anaplastic Large Cell / Q000188:drug therapy* / Q000628:therapy / Q000821:virology; D012367:RNA, Viral / Q000032:analysis; D012074:Remission Induction; D016879:Salvage Therapy; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000628:therapy / Q000821:virology; D014412:Tumor Virus Infections / Q000188:drug therapy*
chemical_list: C099537:Epstein-Barr virus encoded RNA 1; C106732:Epstein-Barr virus encoded RNA 2; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D012367:RNA, Viral; D000079963:Brentuximab Vedotin; D000069461:Bendamustine Hydrochloride